These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8782744)

  • 1. The contribution of peptides to T cell allorecognition and allograft rejection.
    Benichou G; Fedoseyeva EV
    Int Rev Immunol; 1996; 13(3):231-43. PubMed ID: 8782744
    [No Abstract]   [Full Text] [Related]  

  • 2. Indirect T cell recognition in allograft rejection.
    Bradley JA
    Int Rev Immunol; 1996; 13(3):245-55. PubMed ID: 8782745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of indirect allorecognition in allograft rejection.
    Sayegh MH; Carpenter CB
    Int Rev Immunol; 1996; 13(3):221-9. PubMed ID: 8782743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of polymorphic donor peptides in allograft recognition and rejection.
    Fabre JW
    Immunol Rev; 1996 Dec; 154():21-43. PubMed ID: 9034862
    [No Abstract]   [Full Text] [Related]  

  • 5. Induction of T-cell response to cryptic MHC determinants during allograft rejection.
    Boisgérault F; Anosova NG; Tam RC; Illigens BM; Fedoseyeva EV; Benichou G
    Hum Immunol; 2000 Dec; 61(12):1352-62. PubMed ID: 11163093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human leukocyte antigen-G: immunotolerant major histocompatibility complex molecule in transplantation.
    Khalil-Daher I; Rouas-Freiss N; Carosella ED; Dausset JB
    World J Surg; 2000 Jul; 24(7):819-22. PubMed ID: 10833249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides.
    Fangmann J; Dalchau R; Fabre JW
    J Exp Med; 1992 Jun; 175(6):1521-9. PubMed ID: 1588278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epitope mapping of the indirect T cell response to allogeneic class I MHC: sequences shared by donor and recipient MHC may prime T cells that provide help for alloantibody production.
    Lovegrove E; Pettigrew GJ; Bolton EM; Bradley JA
    J Immunol; 2001 Oct; 167(8):4338-44. PubMed ID: 11591757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides.
    Fangmann J; Dalchau R; Fabre JW
    Transplant Proc; 1993 Feb; 25(1 Pt 1):183-4. PubMed ID: 8438266
    [No Abstract]   [Full Text] [Related]  

  • 10. The influence of two distinct alloresponse pathways on the design of peptide-based strategies for allograft tolerance.
    Benichou G; Tam RC; Soares LR; Popov IA; Garovoy MR; Fedoseyeva EV
    Res Immunol; 1996; 147(6):377-87. PubMed ID: 8903104
    [No Abstract]   [Full Text] [Related]  

  • 11. [The human major histocompatibility complex or HLA complex].
    Lemonnier FA
    Biochimie; 1985 Jan; 67(1):XI-XV. PubMed ID: 2581625
    [No Abstract]   [Full Text] [Related]  

  • 12. Direct and indirect antigen recognition: the pathways to allograft immune rejection.
    Benichou G
    Front Biosci; 1999 May; 4():D476-80. PubMed ID: 10331992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of the immune response with major histocompatability class II peptides via the indirect pathway of allorecognition after kidney and small bowel transplantation.
    Gasser M; Lenhard SM; Otto C; Kist-van Holthe JE; Navarro E; Timmermann W; Ulrichs K; Thiede A; Waaga AM
    Transplant Proc; 2002 Sep; 34(6):2244-5. PubMed ID: 12270384
    [No Abstract]   [Full Text] [Related]  

  • 14. Limited T cell response to donor MHC peptides during allograft rejection. Implications for selective immune therapy in transplantation.
    Benichou G; Fedoseyeva E; Lehmann PV; Olson CA; Geysen HM; McMillan M; Sercarz EE
    J Immunol; 1994 Aug; 153(3):938-45. PubMed ID: 7517977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell recognition of donor class I major histocompatibility complex peptides during allograft rejection.
    Fangmann J; Dalchau R; Sawyer GJ; Priestley CA; Fabre JW
    Transplant Proc; 1993 Feb; 25(1 Pt 1):187-8. PubMed ID: 8438268
    [No Abstract]   [Full Text] [Related]  

  • 16. Indirect T-cell allorecognition: perspectives for peptide-based therapy in transplantation.
    Benichou G; Tam RC; Soares LR; Fedoseyeva EV
    Immunol Today; 1997 Feb; 18(2):67-71. PubMed ID: 9057356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptides derived from alpha-helices of allogeneic class I major histocompatibility complex antigens are potent inducers of CD4+ and CD8+ T cell and B cell responses after cardiac allograft rejection.
    Shirwan H; Leamer M; Wang HK; Makowka L; Cramer DV
    Transplantation; 1995 Feb; 59(3):401-10. PubMed ID: 7871571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble HLA class I molecules as immune regulators in transplantation.
    Abdelnoor AM
    Transplant Proc; 2001 Aug; 33(5):2850-1. PubMed ID: 11498185
    [No Abstract]   [Full Text] [Related]  

  • 19. PD-L1/PD-1 signal deficiency promotes allogeneic immune responses and accelerates heart allograft rejection.
    Wang W; Carper K; Malone F; Latchman Y; Perkins J; Fu Y; Reyes J; Li W
    Transplantation; 2008 Sep; 86(6):836-44. PubMed ID: 18813109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The puzzling success of allograft tympanoplasty. Possible immunological explanations.
    Coulie PG; Ars B
    Acta Otorhinolaryngol Belg; 1990; 44(1):3-5. PubMed ID: 2239258
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.